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ABSTRACT (233 words) 
[Background] Mortality subsequent to a hospitalization for heart failure is reported to be much lower in 
Japan than in the United Kingdom (UK). This could reflect differences in disease severity or in management. 
Accordingly, we directly compared patient backgrounds and outcomes between Japan and UK. 
[Methods] Consecutive patients admitted to academic hospitals in the UK and Japan with heart failure had 
a common set of variables, including plasma concentrations of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), collected during admission. Mortality during hospitalizations, at 90- and 180-days was 
recorded and stratified by quintile of NT-proBNP. 
[Results] Overall, 935 patients were enrolled; 197 from UK and 738 from Japan. Median (interquartile 
range) age (UK: 78 [71−88] vs. Japan: 78 [70−84] years; p=0.947), glomerular filtration rate (UK: 49 
[34−68] vs. Japan: 49 [33−65] ml/min/1.73m2; p=0.209) and plasma NT-proBNP (UK: 4957 [2278−10977] 
vs. Japan: 4155 [1972−9623] ng/L; p=0.186) were similar but systolic blood pressure (SBP) was lower in 
the UK (118 [105−131] vs. 137 [118−159] mm Hg; p<0.001). Patients with a higher plasma NT-proBNP 
had a worse prognosis in both countries; in-hospital and post-discharge mortality rates were higher in the 
UK even after adjusting for prognostic variables including NT-proBNP. 
[Conclusions] This analysis suggests that either unobserved differences in patient characteristics or 
differences in care (formal or informal) rather than greater heart failure severity may account for the worse 
outcome of heart failure in the UK compared to Japan. 
 
Keywords: Heart failure; N-terminal pro-B-type natriuretic peptide; international comparison; risk 
stratification; prognosis. 
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INTRODUCTION 
Heart failure is a global problem but patient-outcomes are reported to differ markedly amongst countries,1,2 
despite the similarity of international guidelines on management.3-10 This may reflect differences in the 
severity of heart failure, in the implementation of therapy, in patients’ willingness to adhere to advice or in 
ethnicity and culture. Natriuretic peptides provide an objective measure of the severity and prognosis of 
heart failure and may therefore shed some light on the reasons for observed differences.11-13 Accordingly, 
we compared the outcome of patients hospitalized for heart failure in Japan and the United Kingdom (UK) 
stratified by plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). 
 
METHODS 
Data sources and study cohort 
The characteristics and outcomes of consecutive patients hospitalized for heart failure and who had NT-
proBNP measured were recorded in the West Tokyo Heart Failure (WET-HF) registry and the Hull Lifelab 
registry. Data were collected during 2012 in the UK and between 2011 and 2013 in Japan. WET-HF is an 
ongoing, prospective, multi-center registry of patients admitted for heart failure to five academic hospitals 
in metropolitan Tokyo.14 Data are collected by trained personnel from the patients’ charts and entered using 
a web-based electronic data-capture system. The Hull Lifelab is a large, epidemiologically representative, 
information-rich data-set on the contemporary diagnosis, treatment and natural history of patients with heart 
failure with a main focus on out-patient referrals.15 For this analysis, only patients referred during a 
hospitalization for heart failure were included. 
The clinical diagnosis of heart failure was made by cardiologists with a special interest in heart 
failure at each institution. The British and Japanese data-sets provide similar information. Each study was 
approved by the institutional ethics review boards. In Japan, written informed consent is not mandatory and 
oral informed consent is sufficient based on government rules, for observational studies that use clinical 
information that has already been obtained as a part of usual clinical practice (the report from the Ministry 
of Health, labour and Welfare. in only Japanese.  
www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/). In contrast, written 
informed consent was obtained from all patients in the UK. 
The following data were collected: 1) patient demographics and comorbidities; 2) vital 
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symptoms and signs at presentation; 3) laboratory data including renal function and NT-proBNP measured 
within 3-5 days after admission; 4) left ventricular ejection fraction (LVEF); 5) medication at discharge; 
and 6) in-hospital mortality, 90-day and 180-day post-discharge mortality. The estimated glomerular 
filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease equation.16 
 
Statistical Analysis 
We compared patient characteristics, medication at discharge, and mortality between patients in Japan and 
UK. Categorical variables are expressed as number and percentage, and continuous variables are expressed 
as the mean ± standard deviation (SD) or the median (interquartile range [IQR]), as appropriate. Statistical 
comparisons were performed with unpaired t test or Mann-Whitney test for continuous variables and the 
Pearson’s chi-square test for categorical variables. We constructed a prognostic model using logistic 
regression models rather than Cox proportional hazard models as time-to-event was unknown. Mortality 
by quintile of plasma NT-proBNP was reported for patients from Japan and the UK; quintile ranges were 
constructed from the two populations combined. Univariate prognostic model for log-transformed NT-
proBNP were constructed for in-hospital, 90-day and 180-day post-discharge mortality. A parsimonious 
multi-variable prognostic model for 180-day mortality (102 events) were constructed using country of 
origin and the following nine variables: age, ischaemic heart disease, systolic blood pressure, haemoglobin, 
serum sodium, eGFR, hsCRP, LVEF, and log-transformed NT-proBNP. Additionally, propensity score 
matching analysis was performed to evaluate the influence of country on mortality risks after adjusting for 
the potential imbalance of baseline covariates between countries. Matching was performed using 1:1 
matching protocol without replacement, using callipers of width equal to 0.2 of the standard deviation of 
the propensity score. The balance between the countries in the matching cohort was estimated using the 
absolute standard difference. All probability values were 2-tailed, and values of p <0.05 were considered 
statistically significant. All statistical analyses were performed with SPSS version 24.0 software (SPSS Inc., 
Chicago, Illinois). 
 
RESULTS 
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Overall, 935 patients were enrolled, including 197 from the UK and 738 from Japan. All patients from the 
UK and 712 (97.0%) Japanese patients were followed-up for 180 days after discharge. The age and sex 
distribution of patients enrolled in Japan and the UK were similar (Table 1). However, British patients had 
a higher body mass index, lower systolic blood pressure (both p<0.001) and more often had ischaemic heart 
disease, chronic lung disease and a reduced LVEF compared with Japanese patients. However, GFR (UK: 
49 [34−68] ml/min/1.73m2 vs. Japan: 49 [33−65] ml/min/1.73m2; p=0.209) and plasma NT-proBNP 
concentrations (UK: 4,957 [2,278−10,977] ng/L vs. Japan: 4,155 [1,972−9,623] ng/L) were similar. 
Length of hospital stay (LOHS) was longer in Japan (median [IQR], 13 [9−20] days) compared 
to the UK (median [IQR], 11 [7−18] days) (p=0.018). Fourteen (7.1%) patients in the UK died during 
hospitalization compared with 26 (3.5%) in Japan (p=0.027). Mortality rates at 90 days (25 [13.7%] vs. 36 
[5.1%]) and 180 days (39 [21.3%] vs. 57 [8.3%]) after discharge were substantially higher among British 
patients (p<0.001 for each comparison) (Figure 1). In addition, mortality rates were compared by LVEF 
above and below 45% (Figure 2): there were profound differences in the mortality rates between the Japan 
and UK cohort, especially among patients with LVEF ≥45%. Several differences were observed in terms 
of patient characteristics based on LVEF (Table S1; online supplement): among patients with LVEF ≥45%, 
the British were older and showed a higher level of blood urea nitrogen than that in the Japanese. 
Medication patterns in patients with LVEF ≥45% also differed between the countries. 
In univariate logistic regression models, plasma NT-proBNP was associated with both in-
hospital and post-discharge mortality rates in Japan and UK (Table 2). Mortality rose progressively with 
each higher quintile of NT-proBNP, but within each quintile, mortality was consistently higher amongst 
British compared to Japanese patients (Figure 3). After multivariate adjustment for country as well as other 
prognostic indicators, both log-transformed NT-proBNP and country remained independently associated 
with 180-day post-discharge mortality (Table 3). Even after propensity score matching to further minimize 
the differences between British and Japanese patients (Table S2; online supplement), country (odds ratio 
0.32; 95% confidence interval, 0.13–0.79; p=0.013) was independently associated with 180-day post-
discharge mortality. 
 
DISCUSSION 
This analysis suggests that the prognosis of patients hospitalized for heart failure is much better in Japan 
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than in the UK but this does not appear to be due to differences in the severity of heart failure as reflected 
by plasma concentrations of NT-proBNP. Natriuretic peptides are powerful predictors of both in-hospital 
and post-discharge mortality, as confirmed for both Japanese and British patients in this study.11,12 Mortality 
at 180 days was generally two- to three-times higher within each quintile of NT-proBNP for patients in the 
UK compared to Japan. 
Patients from the UK had several features associated with a worse prognosis including a higher 
prevalence of ischaemic heart disease and chronic lung disease, lower systolic blood pressure and serum 
sodium and higher serum urea and hsCRP but also had other features associated with a better prognosis 
including higher BMI and haemoglobin and slower heart rate. Risk models using similar clinical variables 
have been shown to be powerful prognostic markers both in Japanese patients and those of European 
descent.13,14 However, statistical adjustment in this analysis indicated that observed characteristics only 
partly accounted for differences in outcome in Japan compared to the UK. There were some treatment 
differences, including greater use of loop diuretics, ACE inhibitors or angiotensin receptor blockers, MRA 
and digoxin in the UK and greater use of calcium channel blockers in Japan, perhaps due to a higher 
prevalence of hypertension as reported in other studies in Japan.17,18 However, treatment differences did not 
appear large enough to account for the substantially worse outcome of British patients, especially among 
patients with preserved ejection fraction, although they might perhaps suggest that patients from the UK 
had more advanced heart failure. 
Our data are derived from just a few hospitals but they do appear to reflect national data in their 
respective countries. In Japan, LOHS was shorter in this study compared to historical reports,19 although 
LOHS may be falling for heart failure in Japan.20 Despite a longer LOHS in Japan, which increases the risk 
of in-patient mortality due to the exposure to a greater number of days at risk, in-patient mortality was 
lower in Japan. An analysis of data from the United States have suggested hat LOHS is associated with an 
early readmission after discharge,21 which leads to a higher post-discharge mortality.22 However, the 
National Audit for England & Wales suggested that longer LOHS was associated with an adverse post-
discharge prognosis, probably reflecting more severe disease amongst those with longer LOHS.23 We could 
not identify such a relationship either for Japanese or British patients in our study. This may reflect the 
inability to show small differences due to sample size, differences in reasons for LOHS or post-discharge 
care in Japan and the UK compared to the United States or the absence of any important relationship. LOHS 
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did not result in more patients being discharged on renin-angiotensin-aldosterone system inhibitors or beta-
blockers and, historically, patients in Japan are generally treated with lower doses of medication and thus 
it is difficult to attribute better outcomes in Japan to better treatment due to longer LOHS. The Acute 
Decompensated Heart Failure Syndromes (ATTEND) registry, which is the largest prospective multi-center 
registry in Japan, reported an in-hospital mortality of 6.4% and a 180-day mortality of approximately 
10%,18,24 which is similar to the WET-HF registry. 
This analysis included data from only one British hospital. However, similar results were 
reported from the national audit on heart failure for England & Wales including more than 37,000 patients 
from more than 100 hospitals in 2011−12. The national audit reported a median length of stay on cardiology 
wards of 9 (IQR 5−16) days, an in-hospital mortality of 11% and a 180-day mortality of approximately 
20%.25 Some reports suggest that mortality rates for patients hospitalized with heart failure might be higher 
in the UK than other European countries.26-28 However, the First European Heart Failure survey reported 
the outcome of >8,000 patients and suggested similar mortality of around 14% within 12 weeks of an 
admission for heart failure from most of the 24 countries involved.29 Lower mortalities have been reported 
in some other European,26,27 US28 and Korean30 registries but this may reflect differences in case-
ascertainment which can have a large effect on mortality. 
There are many deficiencies in our data that limit interpretation. The cohorts were relatively 
small but do appear representative of their respective national data. The measurement of NT-proBNP was 
usually performed several days after hospitalisation rather than on admission. However, this may have been 
an advantage as BNP measured later during an admission is a stronger marker of prognosis.31 Differences 
in variables that were not measured or not included in the statistical model (e.g., frailty, nutritional status, 
malignancy, or chronic lung disease) may have accounted for the better prognosis of Japanese patients. For 
example, place of care is a key quality metric for HF. The data from the National Heart Failure Audit for 
England & Wales showed lower in-hospital as well as post-discharge mortality rates for patients treated in 
Cardiology than in General Medicine or other wards.25 In this British cohort, approximately 40% of patients 
with HF were admitted to wards other than Cardiology such as General Medicine wards, and this is in 
agreement with the national data in the UK.23 However, such data were not obtained pertaining to Japanese 
patients in this study. Additionally, the national report showed that British patients were more likely to 
receive specialist follow-up by a cardiologist and/or in a heart failure clinic if treated in a Cardiology ward 
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than in other wards.23 Therefore, these differences might have affected the outcomes in this study. In 
addition, evaluation of the mode of death might have helped clarify differences in the prognosis of HF 
patients between the two countries. Particularly among patients with preserved ejection fraction, further 
research is warranted to confirm this result by performing a study involving a larger population of patients 
with HF. A well-designed study that includes comprehensive information regarding biomarkers (e.g., 
natriuretic peptides, among other such parameters), comorbidities, frailty, social supports and local medical 
systems may provide a better understanding of the discrepancy between the prognosis of British and 
Japanese patients with HF. Doses of medication will have been lower in Japan than in the UK but precise 
data on dose throughout follow-up was not recorded. We have no data on patient-adherence to medical 
advice or differences in lifestyle choices. Ethnic or genetic differences might also have contributed to 
differences in outcome and/or response to therapy. Finally, we cannot exclude differences in the criteria for 
hospitalisation or referral to specialty services or in case-selection. Clearly, these preliminary data require 
confirmation. 
 
CONCLUSIONS 
Important differences exist in patient characteristics, management and outcomes for patients hospitalised 
with heart failure in Japan compared to the UK but the distribution and prognostic significance of post-
admission plasma concentrations of NT-proBNP were similar. Patients in the UK had a substantially higher 
mortality even after adjusting for plasma NT-proBNP. If the reasons for the difference in mortality can be 
identified and are modifiable, this might help improve the outcome of patients with heart failure in the UK. 
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Figure Legends 
 
Figure 1. In-hospital, 90-day and 180-day post-discharge mortality rates for patients hospitalized for heart 
failure in Japan and The United Kingdom. 
 
Figure 2. In-hospital, 90-day and 180-day post-discharge mortality rates based on left ventricular ejection 
fraction (LVEF): (A) LVEF <45% and (B) LVEF ≥45%. 
 
Figure 3. The mortality rates according to quintiles of plasma concentration of NT-proBNP for the: (2-A) 
in-hospital mortality; (2-B) 90-day post-discharge mortality; (2-C) 180-day post-discharge mortality. NT-
proBNP; N-terminal pro-B-type natriuretic peptide. Quintile ranges were <1641, 1641−3255, 3255−6090, 
6090−12340 and >12340 ng/L for the two populations combined. 
